Exploring the Chemical Space around the Privileged Pyrazolo[3,4‑<i>d</i>]pyrimidine Scaffold: Toward Novel Allosteric Inhibitors of T315I-Mutated Abl
2014-04-14T00:00:00Z (GMT) by
A library of pyrazolo[3,4-<i>d</i>]pyrimidines, endowed with a high level of molecular diversity, has been developed applying a synthetic sequence that allowed C3, N1, C4, and C6 substitution. The enzymatic screening of this “privileged scaffold”-based compound collection, validated the use of a diversity-oriented approach in a field characteristically explored by target-oriented synthesis. In fact, several compounds showed high activity against the selected kinases (i.e., Src, Abl <i>wt</i>, and T315I mutated-form), furthermore and interestingly a new compound has emerged as an allosteric inhibitor of the T315I mutated-form of Abl, opening up new opportunities for the development of a novel class of noncompetitive inhibitors of Abl (T315I).